Definium Therapeutics, Inc.: stock overview

DFTXNASDAQBasic materials · Medicinal Chemicals & Botanical Products

Price

$29.38

November 17, 2026Market cap $4.0B

What Ploutos Investor adds for Definium Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

In short

It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.

Its SEC filings
Market cap
$4.0B
137M shares
P/E
–
Revenue, 12 months
–
Net margin
–

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

Fiscal years in figures

DFTX's revenue, profit, cash flow and dividend with each year-end price, from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $525M
$4.0B
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 2.2
4.2
FCF yield 
–
Earnings yield 3-year median: -22.1%
–

Profitability

Net margin 
–
ROIC 
-35.2%
ROIC, 5-year average 
-46.1%
ROE 
-64.2%

Growth

Sorry, we do not have enough data

for the “Growth” group

Balance sheet

Cash 
$1.0B
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
-34.0x
Current ratio 
15.53

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+32.3%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Definium Therapeutics, Inc.
Exchange
NASDAQ
Industry (SIC)
2833 · Medicinal Chemicals & Botanical Products
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
137M

Other companies: Basic materials

The largest companies of the same sector, each with its own page.

The Basic materials sectorAll companies

The full analysis

What do Definium Therapeutics's filings show?

These are Definium Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about DFTX

Didn't find what you were looking for?

Ask us
What is DFTX's market cap?

Definium Therapeutics, Inc.'s market cap is $4.0B, at a price of $29.38 on November 17, 2026 and 137M shares.

Does DFTX pay a dividend?

No. Definium Therapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Definium Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.